Skip to main content
. 2021 Aug 10;9(8):990. doi: 10.3390/biomedicines9080990

Figure 10.

Figure 10

Histopathological assessment of tumor masses sections in (A) HCT116 colon cancer cells implant and (B) MDA-MB-231-Luc breast cancer cells implant treated with costunolide (COS), doxorubicin (DOX), costunolide + doxorubicin (COS + DOX), costunolide-nanoparticles (COS-NPs), and costunolide-nanoparticles + doxorubicin (COS-NPs + DOX). Yellow arrows refer to viable cancer cells. Scale bar shows magnification 40×.